Ketamine

1. 2026-10-19issueIssued info_card
2. 2026-09-27runbrief run
3. 2026-09-27revisionr1.a1
4. 2026-09-24srcWhat urologists need to know about ketamine-induced uropathy: A systematic review
5. 2026-09-24srcChronic ketamine abuse is associated with orexin-A reduction and ACTH elevation
6. 2026-09-24srcOral ketamine may offer a solution to the ketamine conundrum
7. 2026-09-24srcPopulation pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing
8. 2026-09-24srcKetamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
9. 2026-09-24srcKetamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress
10. 2026-09-24srcMechanisms of ketamine and its metabolites as antidepressants
11. 2026-09-24srcIs persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia?
12. 2026-09-24srcSub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors
13. 2026-09-24srcEvaluation of sigma receptors in the antidepressant-like effects of ketamine in vitro and in vivo
14. 2026-09-24srcAntidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor
15. 2026-09-24srcCYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
16. 2026-09-24srcDrug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases
17. 2026-09-24srcSimilar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia
18. 2026-09-24srcPlasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression
19. 2026-09-24srcNMDAR inhibition-independent antidepressant actions of ketamine metabolites
20. 2026-09-24srcDisruption of Cav1.2-mediated signaling is a pathway for ketamine-induced pathology
21. 2026-09-24srcThe clinical toxicology of ketamine
22. 2026-09-24srcReal-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression
23. 2026-09-24srcKetamine-induced biliary dilatation: from Hong Kong to New York
24. 2026-09-24srcChiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects
25. 2026-09-24srcHistory of anaesthesia [Ketamine history editorial]
26. 2026-09-24srcChronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys
27. 2026-09-24srcCharacteristics and circumstances of death related to the self-administration of ketamine
28. 2026-09-24srcKetamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)
29. 2026-09-24srcEsketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
30. 2026-09-24srcPossible pathophysiology of ketamine-related cystitis and associated treatment strategies
31. 2026-09-24srcRifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine
32. 2026-09-24srcmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
33. 2026-09-24srcSynaptic Dysfunction in Depression: Potential Therapeutic Targets
34. 2026-09-24srcA Case of Hepatotoxicity Induced by Therapeutic Ketamine Use for Sedation
35. 2026-09-24srcAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
36. 2026-09-24srcAntidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
37. 2026-09-24srcAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
38. 2026-09-24srcGender differences in subjective discontinuation symptoms associated with ketamine use
39. 2026-09-24srcActivation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions
40. 2026-09-24srcKetamine: 50 Years of Modulating the Mind
41. 2026-09-24srcS-Ketamine Oral Thin Film-Part 1: Population Pharmacokinetics
42. 2026-09-24srcNorketamine, the Main Metabolite of Ketamine, Induces Mitochondria-Dependent and ER Stress-Triggered Apoptotic Death in Urothelial Cells
43. 2026-09-24srcKetamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug
44. 2026-09-24srcHepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions
45. 2026-09-24srcKetamine-Induced Cholangiopathy With Concomitant Hemorrhagic Cystitis
46. 2026-09-24srcAntidepressant effects of ketamine in depressed patients
47. 2026-09-24srcEffects of ketamine in normal and schizophrenic volunteers
48. 2026-09-24srcPostmortem blood ketamine distribution in two fatalities
49. 2026-09-24srcDopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
50. 2026-09-24srcA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
51. 2026-09-24srcInteraction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors
52. 2026-09-24srcNorketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord
53. 2026-09-04issueIssued emergency
54. 2026-09-04issueIssued info_card
55. 2026-09-04issueIssued notice
56. 2026-06-04proposal59 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
57. 2026-06-04publicationPublication — backfill
58. 2026-04-20revisionRevision 1
59. 2026-04-20genGeneration — pipeline-v5 · with 1 morepipeline-v5
60. 2026-04-20rungeneration run
61. 2026-04-20rungeneration run

The same entries, as forms: six forms.